Quantinno Capital Management LP Acquires 15,364 Shares of Globe Life Inc. $GL

Quantinno Capital Management LP increased its stake in Globe Life Inc. (NYSE:GL) by 18.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 97,518 shares of the company’s stock after purchasing an additional 15,364 shares during the quarter. Quantinno Capital Management LP’s holdings in Globe Life were worth $13,572,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of GL. Compound Planning Inc. lifted its position in Globe Life by 4.3% during the 4th quarter. Compound Planning Inc. now owns 1,968 shares of the company’s stock worth $275,000 after acquiring an additional 82 shares during the last quarter. Root Financial Partners LLC grew its holdings in Globe Life by 23.3% in the 1st quarter. Root Financial Partners LLC now owns 439 shares of the company’s stock valued at $61,000 after buying an additional 83 shares during the last quarter. Transcend Capital Advisors LLC grew its holdings in Globe Life by 3.9% in the 4th quarter. Transcend Capital Advisors LLC now owns 2,265 shares of the company’s stock valued at $317,000 after buying an additional 84 shares during the last quarter. Natural Investments LLC increased its position in Globe Life by 2.6% in the 4th quarter. Natural Investments LLC now owns 3,452 shares of the company’s stock worth $482,000 after buying an additional 87 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in shares of Globe Life by 5.6% during the fourth quarter. Parallel Advisors LLC now owns 1,651 shares of the company’s stock worth $231,000 after buying an additional 87 shares during the last quarter. Institutional investors own 81.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Jefferies Financial Group upped their target price on shares of Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a research note on Friday, July 10th. Piper Sandler lifted their target price on Globe Life from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 15th. Wells Fargo & Company upped their price objective on Globe Life from $172.00 to $193.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. JPMorgan Chase & Co. raised their target price on Globe Life from $181.00 to $201.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Finally, Keefe, Bruyette & Woods lowered their price target on Globe Life from $192.00 to $190.00 and set an “outperform” rating on the stock in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $191.67.

Insider Buying and Selling

In other Globe Life news, CEO James Matthew Darden sold 50,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $182.43, for a total value of $9,121,500.00. Following the completion of the sale, the chief executive officer owned 58,451 shares in the company, valued at approximately $10,663,215.93. This trade represents a 46.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Frank M. Svoboda sold 10,000 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $166.68, for a total transaction of $1,666,800.00. Following the completion of the transaction, the chief executive officer directly owned 54,020 shares of the company’s stock, valued at approximately $9,004,053.60. This represents a 15.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 219,174 shares of company stock valued at $37,675,349 in the last 90 days. 2.11% of the stock is owned by corporate insiders.

Globe Life Stock Performance

NYSE:GL opened at $184.37 on Tuesday. Globe Life Inc. has a 1 year low of $127.85 and a 1 year high of $191.55. The firm has a 50 day moving average of $172.08 and a 200-day moving average of $154.64. The company has a current ratio of 0.07, a quick ratio of 0.07 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $14.31 billion, a P/E ratio of 12.24 and a beta of 0.48.

Globe Life (NYSE:GL) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $3.61 EPS for the quarter, missing analysts’ consensus estimates of $3.67 by ($0.06). Globe Life had a return on equity of 20.73% and a net margin of 19.58%.The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the company earned $3.05 earnings per share. The firm’s revenue was up 8.0% on a year-over-year basis. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. As a group, sell-side analysts anticipate that Globe Life Inc. will post 15.7 EPS for the current fiscal year.

Globe Life Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.